Persistence of measles neutralizing antibody related to vaccine and natural infection acquired before HIV infection.

Little is known about long-lasting measles protective immunity when exposure to wild-type or vaccine measles virus precedes HIV infection. The results obtained suggest that measles immunity wanes and the lowest measles geometric mean titres (GMT) were significantly associated with measles vaccine-induced immunity in individuals that later developed HIV infection (86% prevalence, GMT 164 mIU/ml) compared to naturally induced immunity in HIV-infected adults (100% prevalence, GMT 340 mIU/ml, P = 0·0082) or non-HIV infected adults (100%, GMT 724 mIU/ml, P = 0·0001), and vaccine-induced immunity in non-HIV-infected adults (100%, GMT 347 mIU/ml, P = 0·017). The study was conducted in an area without wild-type virus circulation since 2000.

[Distribution of genotypes of hepatitis C in the city of Córdoba, Argentina].

Background: Knowledge of Hepatitis C virus genotype (HCV) present in a patient has an epidemiological interest. In addition, it has an important prognostic value that guides the duration and success of treatment.

Aims: To analyze the distribution of genotypes in HCV-positive patients and linking them with the viral load before and after treatment, evaluating sustained viral response.

A novel human adenovirus hexon protein of species D found in an AIDS patient.

To date, human adenoviruses are classified into 53 types (types 1-51 and types 53 and 54), which have been grouped into six species named A through F, and the recently identified type 52 has been proposed as member of a new species, G. Type classification is based on type-specific epitopes within loop 1 (L1) and loop 2 (L2) of the hexon protein, which contain seven hypervariable regions that are responsible for type specificity. In this paper, we present the characterization of an adenovirus strain isolated from a male AIDS patient in Cordoba, Argentina.

[Human herpesvirus-6 circulation in healthy adults and oncologic patients].

The aim of this paper was to assess the prevalence of antibodies to HHV-6 in the general population and study the virus circulation among individuals with cancer, in order to analyze HHV-6 involvement in lymphoproliferative disorders. A total of 200 sera from the general population and 67 from patients with neoplasia were studied. The latter were divided in 3 groups: lymphoma/myeloma, leukemia and non-immune solid tumors.

Evaluation of antibodies against a rubella virus neutralizing domain for determination of immune status.

The protective immune responses against rubella virus (RV) are related to its neutralizing epitopes, an issue that is important to consider when assessing the immune status of patients with remote infection. In the present paper, we compare the antibodies detected by a synthetic-peptide-based enzyme immunoassay (EIA) with antibodies detected by the traditional technique of hemagglutination inhibition (HIA) in patients with remote RV infection. The synthetic peptide used as an antigen (SP15) represents a neutralizing epitope that corresponds to amino acids 208 to 239 of the E1 glycoprotein.

Neutralizing monoclonal antibody to the E1 glycoprotein epitope of rubella virus mediates virus arrest in VERO cells.

The best-known mechanism of action of antibody-mediated virus neutralization is to impede the entrance of viruses to host cells, as determined by neutralization assays. Antibodies may also inhibit the exit of rubella virus (RV) from infected host cells; in this case, the interaction of the antibodies with their domains must occur on the plasma membrane, because antibodies cannot enter the cells. In the present study, we were able to block temporally the exit of virions from RV-infected cells by the binding of monoclonal antibody (mAb) H3 to their surface.

Analysis of viral glycoproteins by glycosidic digestion inside a polyacrylamide gel.

We adapted the method described by Cleveland et al. (1977); (Peptide mapping by limited proteolysis in sodium dodecyl sulphate and analysis by gel electrophoresis. J.

Cell-fusion assay for the detection of rubella virus in Vero cells.

Background And Objectives: Rubella virus (RV) produces a subtle and slow-developing cytopathic effect in Vero cells that is difficult to recognize, especially at low multiplicities of infection. In order to facilitate the detection of RV in cell culture, we standardized a low-pH virus-mediated cell-fusion assay.

Study Design: The incubation periods, temperatures, pH and multiplicity of infection were established.

Presence of a neutralizing domain in isolates of rubella virus in Cordoba, Argentina.

We studied the presence of a neutralizing epitope of rubella virus (RV) in locally circulating strains in Cordoba, Argentina, using binding by the monoclonal antibody (MAb) H3. This epitope is contained in a sequence of the E1 glycoprotein (E1208-239) represented by the synthetic peptide SP15. H3 MAb showed specific binding to SP15 by enzyme-linked immunosorbent assay (ELISA).

[Detection of rubella antibodies in blood samples collected on filter paper].

Congenital rubella syndrome (CRS) could be prevented if young women knew their immune status before pregnancy, contributing in this way to decrease the birth morbidity rate due to CRS among the children. Our objective was to optimize the detection of rubella virus-antibodies by HAI, using an easier and safer method to collect samples of big populations. One hundred specimens, obtained from patients in a pediatric hospital and pregnant women in an institute of Virology were used for this work.

[Isolation of Chlamydia trachomatis and immune response in different populations].

We studied the presence of C. trachomatis-specific IgG and IgM in adults and newborns, respectively, and attempted isolation of the bacteria in cell culture. The determination of antibodies was carried out by an IFA on C.

Different affinity of monoclonal antibodies for conserved neutralizing epitopes on two strains of rubella virus.

There is, apparently, only one serological type of rubella virus (RV) in the population, although several isolates exist with different characteristics. Some authors failed to detect significant differences among RV strains by neutralization, hemagglutination inhibition, and enzyme immunoassay using polyclonal and monoclonal antibodies, but differences in growth, plaque morphology, and temperature sensitivity between vaccine and wild-type strains were shown by Chantler et al. (3) With the purpose of analyzing the possible differences among several strains of RV, we studied the affinity constant of two monoclonal antibodies (MAbs) for two conserved neutralizing epitopes.